In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events.
Ann Intern Med
; 176(7): JC82, 2023 07.
Article
em En
| MEDLINE
| ID: mdl-37399559
ABSTRACT
SOURCE CITATION Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE) two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;4011159-1171. 36871574.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Colite Ulcerativa
Tipo de estudo:
Clinical_trials
/
Etiology_studies
Limite:
Humans
Idioma:
En
Revista:
Ann Intern Med
Ano de publicação:
2023
Tipo de documento:
Article